MOUNTAIN VIEW, Calif., May 13, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced the appointment of J. Martin Carroll and Jorge Plutzky, M.D. to its Board of Directors. Mr. Carroll has more than 35 years of executive level experience in the pharmaceutical industry. He served most recently in key roles at Boehringer Ingelheim (BI) including Head, Global Strategy and Development and President and Chief Executive Officer, U.S. from 2003 through 2011. Dr. Plutzky is a world-renowned leader in the prevention and treatment of cardiometabolic disease. He currently serves as the Director of The Vascular Disease Prevention Program, which includes the Lipid/Prevention Clinic, in the Cardiovascular Medicine Division at Brigham and Women's Hospital, a role he has held since 1996. With the addition of Mr. Carroll and Dr. Plutzky, the VIVUS Board of Directors now consists of nine highly-qualified directors, seven of whom are independent and four of whom have been appointed within the last thirteen months. "Marty and Jorge are well-respected healthcare leaders and outstanding additions to our Board of Directors," said Mark B. Logan, chairman of the Board of Directors of VIVUS. "Together Marty and Jorge bring, among other talents, extensive and valuable experience in commercialization, marketing and clinical studies, and we believe they will make immediate and significant contributions to the Board. We welcome Marty and Jorge and look forward to working closely with them to achieve our strategic objectives." About J. Martin Carroll During his tenure at BI, Mr. Carroll was instrumental in guiding the launch of Spiriva ® and Pradaxa ® in the U.S. In addition, he was involved in the diabetes market through BI's partnership with Eli Lilly and the launch of Tradjenta ®, a novel option for treating type 2 diabetes. Mr. Carroll played a major role in working with the BI board of managing directors to develop strategic approaches for a number of BI businesses, focusing mainly on pharmaceuticals. Prior to Boehringer Ingelheim, Mr. Carroll spent more than 25 years at Merck & Company, from 1976 through 2001, where he held a number of sales and marketing positions of increasing responsibility. Mr. Carroll served as Executive Vice President, where he had responsibility for the sales and managed care groups. Under his leadership, this team increased sales significantly for several key products including Zocor ®, Singulair ®, Fosamax ® and Cozaar ®. Mr. Carroll's experience at Merck also included commercialization of major products such as Prilosec ®, Pepcid ®, Vasotec ®, and Proscar ®. Mr. Carroll formerly served on the board of directors of Accredo Health, a retail specialty pharmaceutical service company that was acquired by Medco Health Solutions. About Jorge Plutzky, M.D. Dr. Plutzky is internationally recognized as an expert in both the basic science and clinical issues related to lipid disorders and cardiometabolic disease. He is known particularly for his broad interdisciplinary background that spans endocrinology and cardiology, and for his extensive experience with biotechnology and pharmaceutical concerns, as well as regulatory affairs. Dr. Plutzky received his M.D. from the University of North Carolina School of Medicine, during which time he completed a National Institutes of Health research fellowship. He completed his internal medicine residency and cardiology fellowship at Brigham and Women's Hospital/Harvard Medical School in Boston. Dr. Plutzky is the recipient of numerous honorary lectureships and awards and is a member of the scientific advisory boards of the Sarnoff Cardiovascular Research Foundation and Ember Therapeutics. He has also been elected to the American Society for Clinical Investigation.